Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment

References

• MurrayTJDiagnosis and treatment of multiple sclerosisBMJ2006332754052552716513709
   PubMed Web of Science ®Google Scholar
• TremlettHZhaoYRieckmannPHutchinsonMNew perspectives in the natural history of multiple sclerosisNeurology201074242004201520548045
   PubMed Web of Science ®Google Scholar
• CrossAHNaismithRTEstablished and novel disease-modifying treatments in multiple sclerosisJ Intern Med2014275435036324444048
   PubMed Web of Science ®Google Scholar
• GajafattoABenedettiMDTreatment strategies for multiple sclerosis: when to start, when to change, when to stop?World J Clin Cases20153754555526244148
   PubMed Web of Science ®Google Scholar
• LugaresiAdi IoiaMTravagliniDPietrolongoEPucciEOnofrjMRisk-benefit consideration in the treatment of relapsing-remitting multiple sclerosisNeuropsychiatr Dis Treat2013989391423836975
   PubMed Web of Science ®Google Scholar
• TobinWWeinshenkerBGStopping immunomodulatory medications in MS: frequency, reasons and consequencesMult Scler Relat Disord20154543744326346792
   PubMed Web of Science ®Google Scholar
• LizánLComellasMPazSPovedaJLMeleticheDMPolancoCTreatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literaturePatient Prefer Adherence201481653166425525341
   PubMed Web of Science ®Google Scholar
• RiñonABuchMHolleyDVerdunEThe MS choices survey: findings of a study assessing physician and patient perspectives on living and managing multiple sclerosisPatient Prefer Adherence2011562964322259240
   PubMed Web of Science ®Google Scholar
• MendelRTraul-MattauschEFreyDDo physicians’ recommendations pull patients away from their preferred treatment options?Health Expect2012151233121323824
   PubMed Web of Science ®Google Scholar
• Clark DetermannDPetrouSMoroDBekker-GrobEWDiscrete choice experiments in health economics: a review of the literaturePharmacoeconomics201432988390225005924
   PubMed Web of Science ®Google Scholar
• JohnsonRFLancsarEMarshallDConstructing experimental design for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task forceValue Health201316131323337210
   PubMed Web of Science ®Google Scholar
• BridgesJFPHauberABMarshallDConjoint analysis applications in health: a checklist of the ISPOR good research practices for conjoint analysis task forceValue Health201114440341321669364
   PubMed Web of Science ®Google Scholar
• HigginsJPTGreenSCochrane handbook for systematic reviews of interventions version 5.1.0 updated March 2011The Cochrane Collaboration2011 Available from: http://handbook.cochrane.org/
   Google Scholar
• JohnsonFRVan HoutvenGÖzdemirSMultiple sclerosis patient’s benefit-risk preferences: serious adverse event risks versus treatment efficacyJ Neurol2009256455456219444531
   PubMed Web of Science ®Google Scholar
• HansonKAAgashivalaNWyrwichKWRaimundoKKimEBrandesDWTreatment selection and experience in multiple sclerosis: survey of neurologistsPatient Prefer Adherence2014841542224729689
   PubMed Web of Science ®Google Scholar
• Glass-MarmorLPapernaTBen-YosefYMillerAChronotherapy using corticosteroids for multiple sclerosis relapsesJ Neurol Neurosurg Psychiatry200778888688817056624
   PubMed Web of Science ®Google Scholar
• ShinglerSLSwinburnPAliSPerardRLloydAJA discrete choice experiment to determine patient preferences for injection devices in multiple sclerosisJ Med Econ20131681036104223730944
   PubMedGoogle Scholar
• UtzKSHoogJWentrupAPatient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysisTher Adv Neurol Disord20147626327525371708
   PubMed Web of Science ®Google Scholar
• WilsonLLoucksABuiCPatient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choicesJ Neurol Sci20143441–2808725037284
   PubMed Web of Science ®Google Scholar
• AizakiHBasic functions for supporting an implementation of choice experiments in RJ Stat Softw201250212425317082
   PubMed Web of Science ®Google Scholar
• OrmeBGetting Started with Conjoint Analysis: Strategies for Product Design and Pricing Research2nd edMadison WIResearch Publishers LLC20105766
   Google Scholar
• DumontJKellerJRSGHB: functions for hierarchical Bayesian estimation: a flexible approach Available from: https://cran.r-project.org/web/packages/RSGHB/index.htmlAccessed March 2016
   Google Scholar
• BridgesJFHauberABMarshallDConjoint analysis applications in health – a checklist: a report of the ISPOR good research practices for conjoint analysis task forceValue Health201114440341321669364
   PubMed Web of Science ®Google Scholar
• International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: guideline for good clinical practice E6(R1)1996 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdfAccessed March, 2016
   Google Scholar
• HauberABJohnsonRAndrewsEBRisk-benefit analysis methods for pharmaceutical decision-making – where are we now?ISPOR Connection2006126 Available from: https://www.rtihs.org/sites/default/files/Hauber,%20Johnson,%20et%20al._2006_Risk-Benefit_ISPOR%20Connections.pdfAccessed March, 2016
   Google Scholar
• Otero-RomeroSRamió-TorrentàLLPericotIOnset-adjusted incidence of multiple sclerosis in the Girona province (Spain): evidence of increasing risk in the south of EuropeJ Neurol Sci20153591–214615026671104
   PubMed Web of Science ®Google Scholar
• WicksPBrandesDParkJLiakhovistskiDKoudinovaTSasaneRPreferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patientsInteract J Med Res201541e625749630
   PubMed Web of Science ®Google Scholar
• WilsonLSLoucksAGipsonGPatient preferences for attributes of multiple sclerosis disease-modifying therapiesInt J MS Care2015172748225892977
   PubMedGoogle Scholar
• BansbackNTrenamanLHarrisonMHow important is mode of administration in treatments for rheumatic diseases and related conditions?Curr Rheumatol Rep201517651425903666
   PubMed Web of Science ®Google Scholar
• VisserLHvan der ZandeAReasons patients give to use or not to use immunomodulating agents for multiple sclerosisEur J Neurol201118111343134921496180
   PubMed Web of Science ®Google Scholar
• VineyRLanesarELouviereJDiscrete choice experiments to measure consumer preferences for health and healthcareExpert Rev Pharmacoecon Outcomes Res2002248996
   Google Scholar
• MorillasCFelicianoRCatalinaPFPatients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experimentPatient Prefer Adherence201591443145826508841
   PubMed Web of Science ®Google Scholar